Sangamo Therapeutics News

Sangamo Therapeutics Q1 2024 GAAP EPS $(0.27) Misses $(0.22) Estimate, Sales $481.000K Miss $6.654M Estimate

Sangamo Therapeutics (NASDAQ:SGMO) reported quarterly losses of $(0.27) per share which missed the analyst consensus estimate of $(0.22) by 22.73 percent. This is a 325 percent decrease over earnings

Benzinga38minutes ago

Sangamo Therapeutics | 10-Q: Quarterly report

Futu News58minutes ago · Announcements

Earnings Flash (SGMO) SANGAMO THERAPEUTICS Reports Q1 Revenue $481,000

04:03 PM EDT, 05/09/2024 (MT Newswires) -- Earnings Flash (SGMO) SANGAMO THERAPEUTICS Reports Q1 Revenue $481,000

MT Newswires16:03 ET

Express News | Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2024 Financial Results

Reuters16:01 ET

Express News | Sangamo Therapeutics Q1 Revenue USD 481 Thousand Vs. Ibes Estimate USD 6.65 Million

Reuters16:01 ET

Express News | Sangamo Therapeutics Q1 Operating Expenses USD 52 Million

Reuters16:01 ET

Express News | Sangamo Therapeutics Q1 Operating Income USD -51.526 Million

Reuters16:01 ET

Express News | Sangamo Therapeutics Q1 Net Income USD -49.089 Million

Reuters16:01 ET

Sangamo Therapeutics 1Q Rev $481,000 >SGMO

Sangamo Therapeutics 1Q Rev $481,000 >SGMO

Dow Jones16:01 ET

Express News | Sangamo Therapeutics Presents Modular Integrase Technology Engineered To Enable Large-Scale Genome Editing

BenzingaMay 9 08:45 ET

Sangamo Therapeutics Presents Next-Generation Modular Integrase Technology Engineered to Enable Large-Scale Genome Editing

Sangamo Therapeutics, Inc. (NASDAQ:SGMO), a genomic medicines company, today presented pre-clinical data showcasing its novel next-generation integrase technology engineered to enable large-scale genome editing.

BusinesswireMay 9 08:05 ET

Sangamo Therapeutics Announces First Quarter 2024 Conference Call and Webcast

Sangamo Therapeutics, Inc. (NASDAQ:SGMO), a genomic medicine company, announced today that the company has scheduled the release of its first quarter 2024 financial results after the market closes on Thursday, May 9,

BusinesswireMay 2 16:15 ET

Express News | Sangamo Therapeutics To Present Neurology-Focused Pre-Clinical Data From Epigenetic Regulation, Capsid Delivery And Genome Engineering Platforms At 27th ASGCT Annual Meeting

Moomoo 24/7Apr 22 16:36 ET

Biotech Roundtable: Who Will Bring the Next CRISPR Drug to Market?

Seeking AlphaApr 2 11:36 ET

Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) Global Clinical Trials Review 2024, Featuring Takeda Pharmaceutical, JCR Pharmaceuticals, GC Corp, RegenxBio, Sangamo Therapeutics and Generium

Yahoo FinanceApr 2 09:48 ET

What You Need To Know About The Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Analyst Downgrade Today

Yahoo FinanceMar 25 14:52 ET

Revenue Downgrade: Here's What Analysts Forecast For Sangamo Therapeutics, Inc. (NASDAQ:SGMO)

Today is shaping up negative for Sangamo Therapeutics, Inc. (NASDAQ:SGMO) shareholders, with the analysts delivering a substantial negative revision to this year's forecasts. There was a fairly drac

Simply Wall StMar 22 15:06 ET

12 Health Care Stocks Moving In Friday's Intraday Session

GainersIMAC Hldgs (NASDAQ:BACK) shares moved upwards by 91.5% to $2.47 during Friday's regular session. The market value of their outstanding shares is at $2.8 million. Virios Therapeutics (NASDAQ:VIR

BenzingaMar 22 13:31 ET

Express News | Sangamo Therapeutics Shares Are Trading Lower After the Company Announced the Pricing of a $24.0 Million Registered Direct Offering

Moomoo 24/7Mar 22 08:06 ET

Analyst Bullish On Gene Therapy-Focused Voyager Therapeutics Sees Best In Class Potential For Its Neurogenetic Medicine Platform

H.C. Wainwright initiated coverage on Voyager Therapeutics Inc (NASDAQ:VYGR), noting a growing franchise of novel, highly-differentiated adeno-associated virus (AAV)-based TRACER capsids with the pote

BenzingaMar 19 14:16 ET